With FDA Guidance Urging Innovation, Will Novel Smoking Cessation Products Surface In US?
Executive Summary
CDER reiterates expectation for multiple trials to demonstrate efficacy for an IND different from approved products, such as route of administration, for smoking cessation or reduction in risk of relapse. Agency offers access to expedited approval pathways by showing significant improvement in efficacy or safety over existing therapies or addressing unmet medical need.
You may also be interested in...
J&J’s Nicorette Becomes World’s First Licensed Vaping And Smoking Cessation Therapy
J&J's OTC nicotene replacemnt therapy brand Nicorette goes from strength to strength in the UK with a world-first approval from the country's medicines regulator for its Quickmist product for vaping cessation.
US HBW Executive Decisions: FDA's Zeller Retires; CHPA, GOED Additions; ACI VP On ITAC3
Mitch Zeller retires more than 30 year career in tobacco policy; Logan Tucker joins CHPA communications director; GOED hires Ashely Becnel as global business development director; ACI VP Kathleen Stanton appointed to Industry Trade advisory committee.
Califf Returns To US FDA Helm As Familiar Consumer Health Regulation Problems Continue
Announcement of Senate confirmation of Robert Califf as commissioner came shortly after FDA announced recalls of products labeled as supplements but spiked with ED drugs. Like those and others recently identified as adulterated, supplements with undisclosed drugs were being found during Califf’s first stint in 2016 and 2017.